Connect with us

News

London tech start-up TaraCares launches revolutionary AI co-pilot MIMI for personalised hormone health

Published

on

Jyoti Sharma at HR Technologies UK Conference in London, April 2024 / MIMOSA was Top 4 Most Innovative HR Tech StartUps
In a groundbreaking move set to transform personal health management, the London-based tech start-up TaraCares has unveiled MIMI (Menopause Information and Management Interface), an advanced AI co-pilot designed to personalise science for users of its B2B2C hormone health and employee wellbeing platform MIMOSA. 

Leveraging cutting-edge responsible AI and a deep understanding of human health, MIMI aims to become an indispensable tool for women and female individuals of all ages seeking to optimise their hormonal wellbeing and health span, from puberty  to post-menopause.

In Beta since 2023, the development of MIMI was funded by an NIHR R&D grant awarded to TaraCares and strategic angel investors from Big Tech and Big 4 Consulting firms. 

MIMI has been successfully tested by individuals and clinicians in the UK, US and India including British Menopause Society (BMS) certified menopause specialists.

“MIMI gives you the freedom, safety and scientific evidence at your fingertips,” said Lisa Watson, advanced specialist nurse and BMS Menopause Specialist at Watson Health Menopause Clinic.

Dr Vikram Talaulikar, reproductive specialist at UCLH, trainer and BMS certified menopause specialist added: “Out of the comparable apps I have seen, MIMOSA stands out as comprehensive, inclusive and easy to use. 

“I am astonished at the accuracy of MIMI. It is first-class and better than some of the clinicians I know!”

MIMI stands out by its ability to meticulously study and monitor user behaviour and symptoms across 29 key determinants of female hormonal health transition. This sophisticated level of monitoring allows MIMI to deliver tailored recommendations and up-to-date research, empowering users with insights that are specifically relevant to their unique health profiles.

MIMI was inspired by founder Jyoti Sharma’s conversations with female C-suite leaders at UNLEASH World in Paris where she discovered that women running some of the largest and successful businesses in the world were being ill-informed by sponsored social media posts, antiquated diagnostic tools as they resort to dwarfed medical expertise and over the counter menopause test kits against RCOG recommendations.

“We are thrilled to introduce MIMI to our corporate customers,” said Sharma, founder and CEO of TaraCares. 

“Our mission is to bridge the gap between complex scientific knowledge and everyday health management. MIMI does just that by providing personalised, actionable insights that can make a real difference in people’s lives.”

The development of MIMI is a significant leap forward in the field of responsible AI. 

Unlike generic health apps, MIMI’s algorithms are designed to prioritise user privacy and data security while delivering highly specific health recommendations. The system continuously learns from the data it collects, improving its accuracy and relevance over time. 

Users interact with MIMI through an intuitive interface on MIMOSA that makes complex scientific information easily understandable. The AI tracks various health indicators, such as sleep patterns, stress levels, physical activity, diet, and more. 

By analysing these factors, MIMI identifies trends and potential issues before they become serious problems, allowing users to take proactive steps toward better health.

MIMI’s personalised approach is particularly valuable for managing hormonal health, a crucial aspect often overlooked by traditional health monitoring systems. 

The 29 determinants that MIMI monitors include hormone levels, menstrual cycles, mood fluctuations, and other critical markers. This comprehensive approach ensures that users receive a holistic view of their health, backed by the latest scientific research.

Early adopters of MIMI have already reported significant benefits, praising the AI for its precision and user-friendly design. Testimonials highlight how MIMI’s insights have led to improved lifestyle choices, better management of hormonal imbalances, and a deeper understanding of personal health.

The launch of MIMI marks a significant milestone in the journey towards personalised healthcare. 

As the tech start-up continues to refine and expand its capabilities, MIMI is set to become an essential tool for anyone looking to take control of their health with the help of advanced, responsible AI technology.

For more information about MIMI and how it can help you personalise your health journey, visit TaraCares’ official website here.

To receive the Femtech World newsletter, sign up here.

Menopause

Hormone therapy users report healthier lifestyles

Published

on

Menopausal women using hormone therapy reported healthier diet, exercise and sleep habits than non-users in a study of more than 10,000 women.

The menopause transition is associated with a higher risk of chronic health conditions and symptoms including hot flushes and problems affecting the urinary and genital systems.

Hormone therapy is often used to manage these symptoms, but it remains unclear whether it affects health outcomes directly or indirectly through changes in health behaviours.

Previous research has produced mixed results, with some studies suggesting that postmenopausal women pay greater attention to maintaining a healthy lifestyle.

 

The cross-sectional analysis examined whether menopause status and hormone therapy use were linked to diet, physical activity and sleep duration.

A cross-sectional study assesses participants at one point in time. It can identify associations but cannot establish whether one factor directly caused another.

Diet, exercise and sleep are described as modifiable health behaviours because people may be able to change them to improve their health.

The researchers found that postmenopausal women who had never used hormone therapy reported eating less fruit and vegetables.

Women who had never used the treatment were also 19 per cent less likely to meet guidelines for muscle-strengthening activity.

Sleep duration was shorter among postmenopausal women who had never used hormone therapy.

Compared with premenopausal and perimenopausal women, the likelihood of meeting sleep guidelines was 14 per cent lower among never-users, 26 per cent lower among current users and 24 per cent lower among past users.

Perimenopause is the transitional period before menopause, when hormone levels and menstrual periods can change.

Researchers said these findings may be linked to higher levels of follicle-stimulating hormone among postmenopausal women who do not use hormone therapy.

They may also relate to lower levels of oestradiol, a form of oestrogen, which have previously been associated with poorer sleep.

Hot flushes and urogenital symptoms can also disrupt sleep, although hormone therapy may ease these symptoms.

Dr Stephanie Faubion, medical director for The Menopause Society, said: “This large observational study underscores that women who use hormone therapy tend to adopt overall healthier lifestyles.

“Although this association may partly reflect better symptom control enabling healthier behaviours, healthy-user bias is likely a significant contributor.

“Women who choose to use hormone therapy are often more proactive in their healthcare and may systematically differ from nonusers in socioeconomic resources, access to care, and health literacy.

“This largely explains why early observational studies of hormone therapy suggested cardiovascular benefits that were not confirmed in subsequent randomised, controlled trials.”

Continue Reading

Ageing

Strength training may lower heart disease risk in women, study suggests

Published

on

Women who do strength training may have a lower risk of major cardiovascular disease, particularly alongside aerobic activity, a study suggests.

Cardiovascular disease is the leading cause of death worldwide. Aerobic activities such as brisk walking, jogging, cycling and swimming are already established ways to help reduce the risk.

Strength or resistance training, also known as RT, is less established as a prevention strategy. It makes muscles work against a force and can involve body weight, free weights, resistance bands or machines.

Current US guidelines recommend at least two days of strength training and 150 minutes of moderate-to-vigorous aerobic activity each week.

They also recommend limiting sedentary behaviour, including prolonged television viewing, which is considered an independent risk factor for cardiovascular disease.

Dr Tianyue Zhang, lead study author and scientist in the department of nutrition at the Harvard T.H. Chan School of Public Health, said: “Despite its established health benefits, RT is often overlooked as a prevention strategy for CVD, and its impact on CVD risk, especially in middle-aged and older women, remains understudied.

“A key question is, how much does it add beyond aerobic activity alone?”

Researchers analysed data from 117,025 women participating in the Nurses’ Health Study and Nurses’ Health Study II.

The two groups had average starting ages of 66.8 and 48.1 years respectively.

The women reported their resistance training every four years, with exercises involving the arms and legs recorded separately.

Time spent watching television was used as the main measure of sedentary behaviour.

The researchers examined exercise and television-viewing habits alongside the incidence of major cardiovascular disease.

Major cardiovascular events included fatal or non-fatal heart attacks, strokes, coronary artery bypass surgery and percutaneous coronary intervention.

Coronary artery bypass surgery redirects blood around narrowed or blocked heart arteries. Percutaneous coronary intervention uses a small balloon, often followed by a stent, to open a narrowed artery.

Higher levels of strength training were associated with a lower risk of major cardiovascular disease, particularly heart attacks.

No statistically significant link with stroke was found when resistance exercise was considered separately.

Women completing at least two hours of strength training a week had a 20 per cent lower risk of major cardiovascular disease and a 44 per cent lower risk of heart attack than those doing none.

Each additional hour a week was associated with a five per cent lower risk of major cardiovascular disease and a 14 per cent lower risk of heart attack.

The associations weakened somewhat after researchers accounted for body mass index and conditions including diabetes, high blood pressure and high cholesterol, but remained clear.

Body mass index, or BMI, compares weight with height and is commonly used to assess whether someone is within a healthy weight range.

Strength training was also linked to additional benefits among women who did aerobic activity.

Women completing at least two hours of strength training and 150 minutes of aerobic activity each week had a 45 per cent lower risk of heart attack than those reporting no physical activity.

Women who met recommendations for strength training, aerobic activity and reduced television viewing had the lowest risks of major cardiovascular disease, heart attack and stroke compared with those who met some or none of the recommendations.

Zhang said: “These findings suggest that, within an already active population, RT is associated with additional reductions in CVD risk above and beyond overall aerobic activity.

“Alongside aerobic activity and reductions in sedentary behaviour, RT may be an important component of public health strategies for cardiovascular prevention in women.”

The study relied on participants reporting their own resistance training, meaning the data may not always have been precise.

Researchers also noted the possible influence of unmeasured factors and the limited diversity of participants.

They were unable to fully separate the effects of the type of resistance training performed from the overall amount completed.

Dr Harlan M. Krumholz, professor at Yale School of Medicine, said: “We have long encouraged resistance training, and this study provides strong evidence to reinforce that message.

“It should be included in a well-rounded health routine to support function and longevity.”

Continue Reading

Pregnancy

Women with pre-eclampsia at increased risk of chronic kidney disease, study finds

Published

on

Women who develop pre-eclampsia face a higher risk of chronic kidney disease and high blood pressure later in life, new research suggests.

The amount of protein found in the urine during pregnancy may help identify those at greatest risk of developing long-term health problems.

Pre-eclampsia usually involves high blood pressure and increased protein in the urine. Some women also experience severe headaches and changes to their vision.

The condition cannot be treated during pregnancy and, in some cases, labour must be induced early to protect both the woman and baby.

The study found that the condition may be linked to longer-term health problems.

Anne Høy Seemann Vestergaard, a medical doctor and PhD at the department of clinical medicine at Aarhus University, said: “What we can see is a clear association between pre-eclampsia and the development of high blood pressure, chronic kidney disease and cardiovascular disease later in life.”

The researchers found that the amount of protein passed in the urine during pregnancy was linked to the risk of developing chronic conditions after giving birth.

Protein in the urine can indicate that the kidneys are not filtering blood normally.

Vestergaard said: “The most surprising finding was how clearly the amount of protein in the urine during pre-eclampsia was linked to the risk of later high blood pressure and chronic kidney disease. Women with moderate to severe protein excretion had a higher risk of both conditions compared with women with low or no protein excretion.”

Among women with pre-eclampsia and moderate to severe levels of protein in the urine, around one in 20 developed chronic kidney disease within 10 years and around one in six developed high blood pressure.

Most women in the study did not develop long-term complications, but the researchers said the increased risk should still be taken seriously because the potential effects can be severe.

Vestergaard said: “At first glance, this may sound like a low number, but it represents a markedly increased risk when the groups are compared. In the group with pre-eclampsia and high levels of protein in the urine, around 1 in 20 women developed chronic kidney disease within ten years, including early stages of the disease, compared with around 1 in 100 in the group with lower or no protein excretion.”

She added: “That is a considerable number in light of the fact that chronic kidney disease is a potentially serious condition that can progress to kidney failure if isn’t diagnosed early.”

The findings suggest women who experience pre-eclampsia may benefit from more systematic monitoring after pregnancy.

Vestergaard said: “Our study suggests that these women may benefit from monitoring of blood pressure and kidney function after pregnancy.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.